Best practices for integrating psychedelic medicines into psychotherapy

Dr. Peter Addy, Psychotherapist

Empirical Evidence and Reliable Insights into a Promising, Emerging Practice

Level 2 out of 3 icon Emerging Practice

This course is based on preliminary data and explores a promising area of research, which is expected to evolve rapidly.


Download an outline

  • 3h of continuing education
  • 23 lessons that last from 5 to 15 minutes each
  • 1 certificate of achievement
  • 1 PowerPoint
  • 1 bibliography
  • 1 course evaluation
  • 4 months unlimited access
  • 7-day money back guarantee
  • 97% of participants who completed the satisfaction survey declare they would recommend this course to a colleague


The last thirty years of pharmaceutical research have been underwhelming, showing only slight improvements, low effectiveness, high rates of relapse and significant side effects. In contrast, psychedelic-assisted psychotherapies are at the forefront of numerous high-quality studies, yielding very promising results and low side effects.

This immersive online course provides mental health professionals with foundational knowledge and practical skills for psychedelic harm reduction and integration therapies focused on patient safety, ethical care, and optimal outcomes.

Through interactive video lessons, case studies, and downloadable resources, you will learn protocols and best practices for therapies utilizing psilocybin, MDMA, and ketamine. Course modules define mechanisms of action, recent clinical research, traditional ceremonial uses, principles of psychedelic harm reduction, techniques for helping clients prepare for sessions, integration methods for lasting benefits, and recommendations for advancing the field.

Clinicians completing this course can knowledgeably advise prospective patients on benefits versus risks and screen for contraindications. By internalizing ethical questions around treatment planning, informed consent, scope of practice, and more through real-world examples, therapists can confidently offer psychedelic harm reduction and integration therapies aligned with patient values and professional codes of conduct.

As access expands, professionals with expertise in these innovative interventions will be uniquely equipped to provide inclusive, specialized support to help individuals overcome PTSD, depression, end-of-life distress, and more. Enroll now to bring psychedelic care into your practice skillfully!

About the expert

Picture of Peter Addy

Dr. Peter Addy is a licensed professional counselor who provides psychedelic integration and harm reduction therapy at his private practice while training psilocybin facilitators in Oregon’s approved program. After conducting psychedelic research at Yale School of Medicine and co-founding the Yale Psychedelic Science Group, he transitioned into clinical practice. Grounding his work in principles of harm reduction and transpersonal psychology, Dr. Addy skillfully supports clients who use psychedelics. His therapy and teaching approach encourages dismantling systems of oppression and inspiring radical compassion. Passionate about equitable access, he wants to empower all people to explore their inner worlds safely.

More →

Learning objectives

  1. Define key terminology related to psychedelic medicines, including mechanisms of action for psychedelics, entheogens, empathogens, and psychoplastogens.
  2. Assess the benefits and risks of psilocybin, MDMA, and ketamine-assisted therapies.
  3. Apply preparation, intention setting, and integration techniques to provide psychedelic harm reduction aligned with ethical guidelines and scope of practice.
  4. Examine strategies to improve access, education, and service quality of psychedelic-assisted therapies for patients and clinicians.

Learning material

A theoretical course illustrated with clinical examples. This course is composed of videos of 5 to 15 minutes each. The PowerPoint of the course to download.


  • PowerPoint
  • 1. Presentation
  • Psychedelics Introduction

  • 2. Definition of Key Terms
  • 3. What are Psychedelics
  • Background on Psychedelic Renaissance

  • 4. Legal Status and Access in Canada
  • 5. Promising Clinical Applications
  • 6. Psilocybin Recent Clinical Research
  • 7. MDMA Recently Completed Research
  • 8. Ketamine Recent Clinical Research
  • 9. Indigenous Use- How they Work in Culture
  • 10. Principles of Psychedelic Harm Reduction
  • 11. Relative and Specific Risks
  • Preparation and Intention Setting

  • 12. What is transpersonal psychology
  • 13. How Does Spirituality Function within your Client
  • 14. Intention Setting
  • 15. Integration Techniques
  • 16. Evidence-Based Clinical Skills for Better Treatment
  • Considerations for your Practice

  • 17. The Different Roles
  • 18. Ethical Considerations
  • 19. Real Life Clinical Case Example 1
  • 20. Real Life Clinical Case Example 2
  • 21. Real Life Clinical Case Example 3
  • 22. Future Directions
  • 23. Conclusion
  • Bibliography

CE Credits

Download a certificate of successful completion.


This training is intended for mental health professionals.

What our customers are saying

« Course was very interesting and informative problem. I believe us as a therapist is understanding how to deal with some of the issues that he presented, and he being a specialist could perhaps come up with the best practises for these type of situations instead of saying well, what would you do, especially if we’re not an expert in this area there is lies the disappointment in this course »

A (Canada)


  • 3h of continuing education
  • 23 lessons that last from 5 to 15 minutes each
  • 1 certificate of achievement
  • 1 PowerPoint
  • 1 bibliography
  • 1 course evaluation
  • 4 months unlimited access
  • 7-day money back guarantee

Legal notice

The courses offered by ASADIS are accredited by different professional organisations. In addition, ASADIS is approved by the Canadian Psychological Association to offer continuing education for psychologists. ASADIS maintains responsibility for the program.

The CPA’s approval of an individual, group, or organization as a CE Sponsor or Provider is restricted to the activities described in the approved application or annual report form. The CPA’s approval does not extend to any other CE activity the Sponsor or Provider might offer. In granting its approval, the CPA assumes no legal or financial obligations to Sponsors, Providers, or to those individuals who might participate in a Sponsor or Provider’s CE activities or programs. Further, responsibility for the content, provision, and delivery of any CE activity approved by the CPA remains that of the CE Sponsor or Provider. The CPA disclaims all legal liability associated with the content, provision, and delivery of the approved CE activity.

Want to know when new courses are available?

Sign up to our mailing list →

Upon joining, you'll receive a 25% welcome promo code, and you can always unsubscribe at any time!

Find us on: LinkedIn   Facebook   Instagram